Scholarlink

Objectives <p>The aim of study was to determine the occurrence and risk factors of latent (LTBI) and manifest tuberculosis infection (MTBI) in patients with rheumatoid arthritis (RA) treated with biologic and targeted-synthetic disease-modifying drugs (b/tsDMARDs) in Slovakia.</p> Methods <p>Retrospective observational study included 689 patients with moderate-to-severe RA treated with b/ts DMARDS, screened for LTBI.</p> Results <p>The prevalence of of LTBI before the initiation of b/tsDMARDs was 10.3%. During subsequent treatment with b/tsDMARD, LTBI was diagnosed in another 12% of remaining patients (17,9 cases/1000 patient-years of treatment). Patients diagnosed with LTBI were older (64.2 ± 12.4 vs 60.9 ± 12.8, p = 0.02), more often treated with TNF inhibitors (p = 0.032), and had a longer duration of bDMARD/tsDMARD therapy (83.7 ± 44.1 versus 49.2 ± 40.2&#xa0;months, p &lt; 0.001). As many as 73 of 74 patients with LTBI were treated with the first bDMARD/tsDMARD (p &lt; 0.001). Risk factors associated with LTBI were first bDMARD/tsDMARD (OR = 32.5 (95% CI: 6.3–609.6), p = 0.001) and duration of anticytokine treatment (OR 1.013 (CI: 1.007–1.019), p &lt; 0.001). MTBI was diagnosed with an incidence of 0.3% (2 of 689 patients). The proportion of tuberculosis manifestation in previously diagnosed LTBI cases was 1.4%.</p> Conclusion <p>LTBI can affect up to 21% of RA patients treated by b/tsDMARDs. Treatment with the initial bDMARD, TNF inhibition, and the duration of anticytokine therapy have been identified as risk factors for LTBI occurence. The incidence of MTBI is 1.4%, which demonstrates the high effectiveness of chemoprophylaxis in preventing the activation of tuberculosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Latent and Manifest Tuberculosis in Patients with Rheumatoid Arthritis Treated with Anticytokine Therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月10日

查看全文
  • Martina Skamlova,
  • Zlata Kmecova,
  • Michaela Kanianska,
  • Ludmila Barekova,
  • Ivan Rybar

摘要

Objectives

The aim of study was to determine the occurrence and risk factors of latent (LTBI) and manifest tuberculosis infection (MTBI) in patients with rheumatoid arthritis (RA) treated with biologic and targeted-synthetic disease-modifying drugs (b/tsDMARDs) in Slovakia.

Methods

Retrospective observational study included 689 patients with moderate-to-severe RA treated with b/ts DMARDS, screened for LTBI.

Results

The prevalence of of LTBI before the initiation of b/tsDMARDs was 10.3%. During subsequent treatment with b/tsDMARD, LTBI was diagnosed in another 12% of remaining patients (17,9 cases/1000 patient-years of treatment). Patients diagnosed with LTBI were older (64.2 ± 12.4 vs 60.9 ± 12.8, p = 0.02), more often treated with TNF inhibitors (p = 0.032), and had a longer duration of bDMARD/tsDMARD therapy (83.7 ± 44.1 versus 49.2 ± 40.2 months, p < 0.001). As many as 73 of 74 patients with LTBI were treated with the first bDMARD/tsDMARD (p < 0.001). Risk factors associated with LTBI were first bDMARD/tsDMARD (OR = 32.5 (95% CI: 6.3–609.6), p = 0.001) and duration of anticytokine treatment (OR 1.013 (CI: 1.007–1.019), p < 0.001). MTBI was diagnosed with an incidence of 0.3% (2 of 689 patients). The proportion of tuberculosis manifestation in previously diagnosed LTBI cases was 1.4%.

Conclusion

LTBI can affect up to 21% of RA patients treated by b/tsDMARDs. Treatment with the initial bDMARD, TNF inhibition, and the duration of anticytokine therapy have been identified as risk factors for LTBI occurence. The incidence of MTBI is 1.4%, which demonstrates the high effectiveness of chemoprophylaxis in preventing the activation of tuberculosis.